Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "乐华娱乐2025年3月以后发布2024年年度财务报告"

Looking for quality documents?
external link icon
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., May 25, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at two upcoming investor conferences. William Blair 41 st Annual Growth Stock conference being held June 1 - 3.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, June 1, at 1:40 p.m. EST.   Jefferies Virtual Healthcare Conference being held June 1 - 3.   Tony J. Hunt, President and Chief Executive Officer and Jon K. Snodgres, Chief Financial Officer, will participate in a fireside chat on Thursday, June 3, at 2:30 p.m. EST. A live webcast of the discussions will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences
external link icon
Repligen Announces CEO Transition Plan
Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024 WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors (“Board”) has approved the planned transition of Tony J. Hunt from Chief Executive Officer (“CEO”) to Executive Chair, effective September 1, 2024. The Company’s Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of Lead Independent Director.
Mr. Hunt has served as Chief Executive Officer and a member of the Company’s Board of
external link icon
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the “2024 Notes”) and certain new investors, pursuant to which Repligen will issue $600 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “New Notes”). Approximately $309.9 million principal amount of the New Notes will be issued in exchange for approximately $217.7 million principal amount of 2024 Notes (the “Exchange Transactions”) and approximately $290.1 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”). The conversion price for the New Notes will initially be approximately $203.06 per share of Repligen’s common stock, which represents a conversion
external link icon
Repligen Corporation to Present at Upcoming June Investor Conferences
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the following June investor conferences.
William Blair’s 44 th Annual Growth Stock Conference being held in Chicago from June 4 – 6, 2024. Tony J. Hunt, Chief Executive Officer, is scheduled to present a company overview on June 5 at 12:00 p.m. CT. Jefferies’ Global Healthcare Conference being held in New York from June 5 – 6, 2024. Olivier Loeillot, President and Chief Commercial Officer and Jason K. Garland, Chief Financial Officer, are scheduled to participate in an analyst-led discussion on June 6 at 11:30 a.m. ET. A live webcast of the conference presentations will be accessible through Repligen’s  Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation
Repligen
external link icon
Repligen to Report Fourth Quarter and Full Year 2023 Financial Results
Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET WALTHAM, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2023 financial results on Wednesday, February 21, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve-month reporting periods ended December 31, 2023. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658
news icon
Repligen Announces CEO Transition Plan
news icon
Repligen Launches the CTech™ SoloVPE® PLUS System
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE® PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers. The SoloVPE PLUS System is engineered to offer unparalleled accuracy, speed, and ease-of-use for at-line ultraviolet-visible (UV-Vis) concentration measurement in complex biological production workflows, from process development scale through cGMP manufacturing.
external link icon
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming investor conferences.
Stifel’s 2021 Virtual Healthcare Conference being held November 15-17. Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Wednesday, November 17, at 8:00 a.m. EST. Stephens Annual Investment Conference being held December 1-3. Jon K. Snodgres, Chief Financial Officer, will participate in a fireside chat on Friday, December 3, at 11:00 a.m. EST.
A live webcast of the discussions will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative
external link icon
Repligen to Present at the 25th Annual Piper Jaffray Healthcare Conference
WALTHAM, Mass., Nov. 26, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the 25 th Annual Piper Jaffray Healthcare Conference on Tuesday, December 3 at 9:50 a.m. EST. The conference will be held December 3-4, 2013 at the New York Palace Hotel in New York. A live audio webcast of the Repligen presentation will be accessible through the Investor Relations section of Company's website at www.repligen.com ; see News & Events, Events & Presentations. This webcast will also be archived for a period of time on the Company's website. About Repligen Corporation Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies
external link icon
Repligen CEO to Present at Jefferies 2013 Global Healthcare Conference
WALTHAM, Mass., May 23, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present a corporate update at the Jefferies 2013 Global Healthcare Conference on Monday, June 3, 2013, at 4:30 p.m. EDT. The conference will take place June 3-6 at the Grand Hyatt New York. The Repligen presentation will be webcast live and can be accessed through the Investors section of Company's website at www.repligen.com . The webcast and slide presentation will also be archived for a period of time on the Company's website. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a